1. Clinical & Scientific Overview
Combined Oral Contraceptives (Ethinylestradiol + Levonorgestrel / Desogestrel) & Centchroman (Ormeloxifene) (TIP-MED-000100, Reference Code [6.10]) is classified under
Thyroid, Pituitary, Adrenal & Hormonal Medicines (Ch 06) as a Combined Estrogen–Progestogen Hormonal Contraceptive & Non-Steroidal SERM Contraceptive (Schedule H | NLEM 2022).
Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 06 [6.10], p. 76): EE + Levonorgestrel: Mala-N / Mala-D (Govt of India), Ovral-L (Pfizer). EE + Desogestrel: Novelon, Femilon. EE + Drospirenone: Yasmin, Crisanta. Centchroman (Ormeloxifene): Chhaya (MoHFW Free Supply), Saheli (HLL), Sevista (Torrent) — Strengths & Dosage Forms: COCs: 21 hormonal tablets (EE 20–30 mcg + LNG 150 mcg / Desogestrel 150 mcg / Drospirenone 3 mg) + 7 iron/placebo tablets. Ormeloxifene: 30 mg, 60 mg tablets
COCs: 21 hormonal tablets (EE 20–30 mcg + LNG 150 mcg / Desogestrel 150 mcg / Drospirenone 3 mg) + 7 iron/placebo tablets. Ormeloxifene: 30 mg, 60 mg tablets
3. Mechanism of Action & Pharmacodynamics
Combined Estrogen–Progestogen Hormonal Contraceptive & Non-Steroidal SERM Contraceptive (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Thyroid, Pituitary, Adrenal & Hormonal Medicines (Ch 06): clinical efficacy is mediated via Combined Estrogen–Progestogen Hormonal Contraceptive & Non-Steroidal SERM Contraceptive (Schedule H | NLEM 2022) for Oral contraception, polycystic ovary syndrome (PCOS), dysmenorrhoea, heavy menstrual bleeding (Ormeloxifene 60 mg is also used for dysfunctional uterine bleeding & mastalgia).
4. Therapeutic Indications & Evidence-Supported Uses
- Oral contraception, polycystic ovary syndrome (PCOS), dysmenorrhoea, heavy menstrual bleeding (Ormeloxifene 60 mg is also used for dysfunctional uterine bleeding & mastalgia)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: COCs: 1 tablet PO daily at the same time for 21 days, followed by 7 pill-free (or iron-tablet) days. Ormeloxifene (Chhaya/Saheli — Contraception): Start on Day 1 of period at 30 mg TWICE weekly for first 12 weeks, then 30 mg ONCE weekly from Week 13 onwards!
Administration & Meal Timing: May be taken with or without food (taking after dinner or at bedtime reduces initial estrogen nausea) | COCs: Fixed daily hour (e.g., 9:00 PM). Ormeloxifene: Fixed day(s) of the week
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Drospirenone-containing COCs (Yasmin/Crisanta) have anti-mineralocorticoid activity and are CONTRAINDICATED in renal impairment! Hepatic: Contraindicated in active liver disease
Renal: Drospirenone-containing COCs (Yasmin/Crisanta) have anti-mineralocorticoid activity and are CONTRAINDICATED in renal impairment! Hepatic: Contraindicated in active liver disease
Renal: Drospirenone-containing COCs (Yasmin/Crisanta) have anti-mineralocorticoid activity and are CONTRAINDICATED in renal impairment! Hepatic: Contraindicated in active liver disease
7. Contraindications, Precautions & High-Risk Warnings
- COCs CONTRAINDICATED (WHO MEC Category 4): Smoking + Age >=35 years, Migraine WITH Aura (high ischaemic stroke risk!), History of DVT/PE or thrombophilia, Uncontrolled HTN (>=160/100 mmHg), Breast cancer, Decompensated cirrhosis, and <6 weeks postpartum while breastfeeding! (Ormeloxifene/Chhaya is non-steroidal, estrogen-free, safe in breastfeeding, and free of VTE/lipid/BP risk!)
Key Clinical Precautions: Renal: Drospirenone-containing COCs (Yasmin/Crisanta) have anti-mineralocorticoid activity and are CONTRAINDICATED in renal impairment! Hepatic: Contraindicated in active liver disease
8. Adverse Effects Profile
- COCs: Nausea, breast tenderness, intermenstrual spotting (first 3 cycles), headache. Ormeloxifene: Prolonged menstrual cycle length (>35–45 days in ~8% of users — reassure patient!)
- COCs: Venous thromboembolism (DVT, PE), ischaemic stroke, myocardial infarction, hypertension, hepatic adenoma, hyperkalaemia (with Drospirenone in CKD/ACEi users)
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CYP3A4 inducers (Rifampicin, Carbamazepine, Phenytoin, Topiramate, Oxcarbazepine) cause CONTRACEPTIVE FAILURE on COCs (use non-hormonal/IUD or DMPA backup!); COCs reduce Lamotrigine plasma levels by 50%!
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Take COC pill at the same time every night; stop immediately if severe calf pain, chest pain, breathlessness, or flashing-light migraine occurs; Chhaya/Saheli is taken twice weekly for 3 months then once weekly and is safe during breastfeeding
- Meal & Clock Timing Instruction: May be taken with or without food (taking after dinner or at bedtime reduces initial estrogen nausea) (COCs: Fixed daily hour (e.g., 9:00 PM). Ormeloxifene: Fixed day(s) of the week)
- Missed Dose Protocol: COC Missed-Pill Rule: If 1 pill missed (<24–48h late), take immediately and continue pack; if >=2 pills missed (>=48h late), take the most recent missed pill immediately, continue pack, and use condoms for the next 7 consecutive days!
- Geriatric Dispensing Pearl: Not indicated in postmenopausal women
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: COCs: 21 hormonal tablets (EE 20–30 mcg + LNG 150 mcg / Desogestrel 150 mcg / Drospirenone 3 mg) + 7 iron/placebo tablets. Ormeloxifene: 30 mg, 60 mg tablets
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 06 [6.10] (p. 76)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [6.6]-C34 Danazol — Systemic Glucocorticoids (Deflazacort, Dexamethasone), Mineraloco
- [6.7]-C35 Dexamethasone — Intermediate-Acting & Long-Acting Systemic Glucocorticoids (Sched
- [6.8]-C36 Fludrocortisone Acetate — Oxazoline Glucocorticoid & Potent Synthetic Mineralocorticoid (Sc
- [6.9]-C37 Medroxyprogesterone Acetate — Oral Synthetic Progestogens & Retroprogesterone (Schedule H | NLE
